Kat Lorentz is an Engineer IV with the allogeneic platform process development team at GentiBio. She brings 12-years of laboratory experience in both the professional and academic settings. She studied cytokine bioprinting onto bone grafts to spatially control remodeling at Carnegie Mellon University. Then in her graduate studies at the University of Pittsburgh, Kat worked on the development of an exosome based vascular graft for use in bypass surgeries. After school, she joined Bristol-Myers Squibb where she was part of the cell therapy process development team supporting multiple early-stage programs before joining Genti.
In her free time, Kat enjoys hiking, kayaking, and baking! After moving to Seattle in 2020, she’s been enjoying the mountains and camping.